Cannabidiol oral solution (Epidiolex, GW Pharmaceuticals) is no longer considered a controlled substance.
A supplemental application for cannabidiol oral solution (Epidiolex, GW Pharmaceuticals and Greenwich Biosciences) has been submitted for the treatment of seizures associated with tuberous sclerosis complex.
Patients with chronic pain using medical cannabis reported less nighttime awakenings initially, but tolerance may build with frequent use.
Osteoarthritis is the most common type of arthritis, affecting nearly 54 million people.
Lack of Quality Evidence Around Cannabis Use Complicates Patient Management in the Health-System Setting
Takeaways from a roundtable at ASHP 2019.
The FDA issued warning letters to several companies marketing their CBD products in ways that violate the Federal Food, Drug, and Cosmetic Act.
Site will offer CBD education and product marketing.
Fifth company warned about unsubstantiated claims this year.
Companies have been promoting unsubstantiated health and treatment claims.
CBD market will grow by over 700% in 2019.